65,437 trials
Heparin-induced Thrombocytopenia Type II
Primary: Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation — 10 participants
Lung Cancer
Primary: Overall Survival — 12.2; 12.1 months
Renal Anemia of Chronic Kidney Disease
Primary: Percentage of Participants Satisfied With Previous Erythropoiesis Stimulating Agent (ESA) Treatment — 83.7 percentage of participants
Hypercholesterolemia
Primary: Percentage of Participants Who Experienced Adverse Events (AEs) — 82.5; 81.0; 19.5; 18.7 percentage of participants
Luteal Hormone Supplementation in In-vitro Fertilization · Embryo Transfer
Primary: Clinical Pregnancy Rate Per Embryo Transfer — 28.5 Percentage of pregnancy/embryo transfer
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: Recurrent VH Incidence (Early and Late) — 22.2; 10.8; 32.4; 11.1 Percentage of participants — p=<0.05
Acute Myelogenous Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Percentage of Participants With Overall Survival — 73; 65 percentage of participants — p=0.17
Acquired Hemophilia A
Primary: Percentage of Serious Bleeding Episodes Responsive to OBI-1 — 100 percentage of serious bleeding episodes — p=<0.001
Ischemic Foot Ulcer
Primary: Ischemic Foot Ulcer — 3; 10 participants
Lipid Metabolism, Inborn Errors · Hypercholesterolemia, Autosomal Dominant · Hyperlipidemias
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) — -28.5; -27; -27.3; -27.9 percent change
Coronary Artery Disease · General Anesthetic Drug Allergy · Coronary Artery Bypass Graft Surgery
Primary: Blood Level of Troponin I — 2.16; 2.57 ng/mL — p=0.02
Condylomata Acuminata
Primary: Human Papillomavirus (HPV) Types in External Genital Warts (EGW) — 80; 12.66; 0.66; 2 percentage of participants
Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray
Primary: Time (in Days) to Wound Closure (Healing) Defined as Skin Re-epithelialization, Without Drainage or Dressing Requirements. — 14.4; 13.3 days to wound closure — p=.3393
HIV
Primary: Lopinovir/Ritonavir Area Under the Concentration-time Curve (AUC0-24) — 196 mcg*hr/mL
Epilepsy
Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.156; 0.128 proportion of participants